News 9 reports that a Tulsa hospital is using Spravato nasal spray alongside antidepressants for people with treatment-resistant depression in a controlled setting.
Tulsa report describes esketamine use
News 9 reports that a Tulsa hospital is using Spravato, an esketamine nasal spray, as an addition to traditional antidepressant treatment for people with treatment-resistant depression.
According to News 9, the hospital is using the nasal spray to enhance existing antidepressant approaches rather than describing it as a replacement for traditional antidepressant treatment. The report identifies the patients involved as people with treatment-resistant depression.
Clinicians report symptom improvement
Medical practitioners cited by News 9 said the added treatment can help reduce symptoms of anxiety and severe depression. News 9 reports that many patients have seen positive results while receiving care in a controlled observation setting.
The source does not provide patient numbers, treatment timelines, or additional details about how results were measured. Its account centers on practitioners’ reports about use of Spravato alongside antidepressants in the Tulsa hospital setting.
Treatment is observed in a controlled setting
News 9 describes the treatment as taking place under controlled observation. The report links that setting to the hospital’s effort to better help people with major depressive disorder and treatment-resistant depression.
The source reports on a treatment approach involving esketamine nasal spray and traditional antidepressants. It does not describe broader availability of the approach outside the hospital setting discussed in the article.
What this means for Oklahoma patients
For Oklahomans looking for treatment locally, the directory lists 20 published clinics in Oklahoma. News 9’s report indicates that a Tulsa hospital is using an observed Spravato approach alongside antidepressant treatment for treatment-resistant depression.
This is general information, not medical advice.
More Oklahoma reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.